Out Now! 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
2022 | HFSA

HFSA Releases Review Examining the Growing Economic Burden of Heart Failure in the United States

HFSA News Journal of Cardiac Failure

ROCKVILLE, MARYLAND (January 24, 2022) - Today, the Heart Failure Society of America (HFSA) released a review, Economic Issues in Heart Failure in the United States, in the Journal of Cardiac Failure (JCF). The review examines the growing economic burden of heart failure for patients and the health care system in the United States, providing a summary of evidence for the cost-effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure.
 
The HFSA Advocacy Committee developed the review to support their advocacy of high value care and to provide a roadmap for maximizing benefits for patients with heart failure within a limited health care budget. It highlights the economic impact of heart failure exploring hospitalization trends, readmission, transitions of care, outpatient trends, disparities, and the impact of the COVID-19 Pandemic.
 
“Despite remarkable recent advances in the treatment of heart failure, the high cost of care limits delivery of effective care,” said Paul Heidenreich, MD, MS, lead author, Chair of the HFSA Advocacy Committee and Professor and Vice Chair for Quality in the Department of Medicine at Stanford University. “This review pulls together the summary of evidence to allow for decision making that leads to the best results for patients’ health and the healthcare system.”
 
Economic Issues in Heart Failure in the United States sheds light on the important role of price, cost-effectiveness, and the value of diagnosis and treatment, which HFSA and JCF leadership recognize as critical components of caring for patients with heart failure. 
 
The paper Economic Issues in Heart Failure in the United States was published online in the Journal of Cardiac Failure, the official journal of the Heart Failure Society of America (HFSA) and the Japanese Heart Failure Society (JHFS). It will be published in the March 2022 print issue. It can be accessed via the JCF online or the HFSA Scientific Statements webpage.

Coauthors: Paul A. Heidenreich MD, MS; Gregg C. Fonarow MD; Yekaterina Opsha PharmD BCPS- AQ Cardiology; Alexander T. Sandhu MD; Nancy K. Sweitzer MD, PhD; Haider J. Warraich MD
 
DOI: https://doi.org/10.1016/j.cardfail.2021.12.017